DOT adds opioids, methamphetamines to drug test requirements

Nov. 15, 2017
DOT updates drug test requirements by adding opioids and methamphetamines

The Department of Transportation announced in the November 13 Federal Register that it is amending its drug-testing program regulation to add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine as an initial test analyte; and remove methylenedioxyethylamphetamine as a confirmatory test analyte. The changes are effective January 1, 2018.

The revision of the drug-testing panel harmonizes DOT regulations with the revised HHS Mandatory Guidelines established by the US Department of Health and Human Services for Federal drug-testing programs for urine testing. This final rule clarifies certain existing drug-testing program provisions and definitions, makes technical amendments, and removes the requirement for employers and consortium/third-party administrators to submit blind specimens.

In addition:

  • DOT now will require all personnel involved in the drug testing process to subscribe to the ODAPC email list-serve; drug testing personnel will be able to demonstrate knowledge of the most recent drug testing rules by displaying a copy of the most recent list serve email;
  • DOT recommends retaining a paper copy of the full Part 40 regulations as a best practice;
  • DOT will allow Medical Review Officers (MRO) to perform a secondary test to determine whether a positive marijuana test is due to smoking marijuana, a Schedule I illegal drug, or use of Marinol a Schedule III prescribed drug. 

New fatal flaws:

The specimen has no Drug Testing Custody & Control Form (CCF),
Multiple collections were conducted using only one CCF, and
There was no specimen submitted to the laboratory with the CCF.